Stock Information
symbol line chart

SIShoulder Innovations Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Robert Ball

Location

Michigan, USA

Exchange

NYSE

Website

https://shoulderinnovations.com/

Summary

We are a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market.

Company Info

CEO

Robert Ball

Location

Michigan, USA

Exchange

NYSE

Website

https://shoulderinnovations.com/

Summary

We are a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market.

AI Insights for SI
3 min read

Quick Summary

Shoulder Innovations Inc is a commercial-stage medical technology company focused exclusively on the shoulder surgical care market. The company develops and sells advanced implant systems used in shoulder arthroplasty procedures, which are surgeries that replace or reconstruct damaged shoulder joints. Its products are primarily aimed at orthopedic surgeons, hospitals, ambulatory surgery centers, and healthcare systems that treat patients with severe shoulder arthritis, trauma, rotator cuff disease, or failed prior shoulder procedures. The company is based in Michigan, with principal executive offices described as being in Grand Rapids and company data listing Holland, Michigan as its city. Shoulder Innovations is still operating at a loss, with reported operating revenue of about $17.2 million, gross profit of about $13.4 million, and net income of about negative $10.2 million for the reported period.

The Bull Case

  • Shoulder Innovations’ main strength is its focused strategy in the shoulder surgical care market.
  • Unlike diversified orthopedic companies, it can concentrate its research, surgeon education, and commercial messaging on shoulder arthroplasty.
  • The company also has a high gross profit relative to revenue in the reported data, with gross profit of about $13.4 million on revenue of about $17.2 million.
  • That suggests the underlying product economics could be attractive if the company can scale sales while controlling operating expenses.
  • Its specialized positioning may appeal to shoulder surgeons who want purpose-built systems rather than products that are one category inside a much larger orthopedic catalog.

The Bear Case

  • Shoulder Innovations’ most obvious weakness is that it is not yet profitable.
  • The company reported negative operating income of about $10.0 million and negative net income of about $10.2 million for the period provided.
  • Its diluted EPS of negative $0.49 and earnings yield of zero indicate that valuation is based on future growth rather than current earnings.
  • The company is also small, with only 61 employees, which may limit its ability to match the sales reach, clinical research budgets, and hospital-contracting power of larger competitors.
  • Its narrow focus on shoulder surgery can be a strength, but it also creates concentration risk if product adoption slows or if competitors respond aggressively.

Key Risks

  • The company faces significant competition from large orthopedic device manufacturers with greater financial resources, broader sales forces, and deeper hospital relationships.
  • Shoulder Innovations is also operating at a loss, so it may need to manage cash carefully or potentially raise capital if losses continue.
  • Any slowdown in surgeon adoption, reimbursement pressure, product quality issue, supply disruption, or unfavorable clinical outcome data could harm growth.
  • The stock may also be volatile because its valuation depends heavily on future revenue expansion rather than current earnings.

What to Watch

UpcomingThe most recent fundamental period provided is Q3 2026, during which Shoulder Innovations reported operating revenue of about $17.2 million and gross profit of about $13.4 million.
UpcomingThe company also reported total operating income of about negative $10.0 million and net income of about negative $10.2 million, showing that it remained in an investment and commercialization phase.
UpcomingNo specific new product launch, acquisition, regulatory event, or partnership for Shoulder Innovations was included in the supplied company data.
ExpectedIn the next quarter, investors will likely focus on whether Shoulder Innovations can continue expanding revenue from its shoulder arthroplasty implant systems.

Price Drivers

  • Shoulder Innovations’ stock price is likely being driven by revenue growth expectations, surgeon adoption, gross margin, and the company’s path toward profitability.
  • The company has a market capitalization of about $399 million, reported revenue of about $17.2 million, and an EV-to-revenue ratio of about 5.24, which suggests investors are pricing in meaningful future growth.
  • The company is not profitable, with diluted EPS of negative $0.49 and net income of about negative $10.2 million, so the market will likely react strongly to cash burn, operating leverage, and any indication of improving losses.
  • Its 52-week range of $10.92 to $24.60 shows that the stock has had substantial volatility, which is common for smaller medical technology companies.

Recent News

  • The supplied recent news does not appear to contain clearly verified news about Shoulder Innovations Inc.
  • One item discusses SI-BONE and the ticker SIBN, including a Needham price target increase, 2025 revenue growth, product launches, and a Smith & Nephew partnership.
  • Another item discusses Quantum-Si and a potential $300 million shelf registration, which is unrelated to Shoulder Innovations’ shoulder implant business.
  • A final item discusses a luxury watch retailer and has no apparent connection to Shoulder Innovations or the medical device market.

Market Trends

  • The broader orthopedic implant market is being shaped by aging demographics, rising joint replacement demand, and greater patient expectations for restored mobility.
  • Shoulder arthroplasty is a specialized but growing area within orthopedics, supported by improved implant designs, surgeon training, and expanded acceptance of reverse shoulder replacement techniques.
  • At the same time, hospitals and ambulatory surgery centers are increasingly focused on cost efficiency, vendor consolidation, clinical outcomes, and reimbursement economics.
  • Smaller medtech companies can gain share if they offer clearly differentiated technology, but they must overcome entrenched relationships held by larger orthopedic vendors.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on SI

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@CopyRemarkable14 7 months ago

Gold Tops $5,000 in Historic Bull Rally

Gold Tops $5,000 in Historic Bull Rally

Gold prices have surged past $5,000 an ounce for the first time ever, continuing a stunning and fast-moving rally that’s taken many by surprise. Investors are piling into precious metals as concerns grow over global debt, inflation, geopolitical uncertainty, and currency weakness. This move has been described by analysts as part of a broader “debasement trade” as the dollar weakens and safe haven demand accelerates. Gold’s rally this year follows a massive gain in 2025, underlining just how strong the trend has become. With also hitting new highs, the precious metals complex is drawing attention from traders looking for protection and diversification amid macro uncertainty. Does gold’s break above this massive milestone signal a new long-term era for safe havens, or is it just a blow-off move that could retrace fast?

No more topics to show